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OBJECTIVES: The purpose of this study was to evaluate the
cost-effectiveness of adjuvant trastuzumab treatment of HER2+
early stage breast cancer (ESBC) patients from the perspective of
the Belgian health care authorities. METHODS: An existing
Markov model, comparing 1 year adjuvant trastuzumab treat-
ment to current therapy and simulating disease progression over a
lifetime perspective, was adapted to the Belgian context. The
model included 5Markov states (disease free survival, recurrence,
metastasis, cardiac side effects, death) and three temporary 1-cycle
states preceding respectively the aforementioned recurrence,
metastasis and cardiac side effects states. Transition probabilities
were obtained from the EU registration trial (HERA). Health
beneﬁts were expressed in quality-adjusted life years (QALY)
gained, future beneﬁts were discounted at 1.5%. QALY-weights
were obtained from published literature. Costs were calculated
from the perspective of the Belgian health care budget (year 2005),
future costs were discounted at 3%. Costs were obtained from the
IMS Belgian Hospital Disease Database (longitudinal database,
representative panel of 37 hospitals), from an expert opinion
analysis (6 Belgian oncology centers), and from ofﬁcial data
sources and published literature. A deterministic incremental
cost-effectiveness ratio (ICER) was calculated for 5 different age
categories (<50, 50–59, 60–69, 70–79 and 80 years). Conﬁ-
dence intervals (95% CI) were estimated by probabilistic sensitiv-
ity analyses. Based on the estimated Belgian age distribution of
HER2+ ESBC patients, an overall deterministic ICER for the
Belgian population of treatment eligible patients was calculated.
RESULTS: The ICER for age categories <50, 50–59, 60–69,
70–79 and 80 years was estimated at respectively €6,520 (95%
CI: €3,704–€10,350), €8,363 (95% CI: €4,793–€13,436),
€12,343 (95%CI: €6,636–€20,224), €24,997 (95%CI: €13,708–
€42,908) and €96,150 (95% CI: €53,944–€206,007) per QALY
gained. The ICER for the total Belgian population of treatment
eligible patients was estimated at €10,315 per QALY gained.
CONCLUSION: Adjuvant trastuzumab treatment of HER2+
ESBCpatients is predicted to be cost-effective from the perspective
of the Belgian health care payer.
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OBJECTIVES: To evaluate the cost-effectiveness of docetaxel
versus the once weekly paclitaxel regimen (Pac-1w) and the
nano-particle bound paclitaxel (Nab-Paclitaxel) from the
National Health Service perspective (UK). METHODS: AA
Markov model was developed to estimate the total treatment
related costs and clinical beneﬁts of taxane treatment for MBC
patients over lifetime. Patients moved through health states of
progression-free survival, progression and death. In absence of
head-to-head clinical trials, indirect comparisonsweremade using
Pac-3w as a common comparator in 3 clinical trials (Jones 2005,
Seidman 2004, Gradishar 2005). Adverse events, dose reduction,
G-CSF use, and post-failure treatment were modelled. Costs of
chemotherapy and utility values for health states and adverse
events were obtained from published literature. Costs came from
2005 NHS reference costs and British National Formulary 2006.
Nab-paclitaxel’s per cycle price was assumed to equal docetaxel’s.
Costs and beneﬁts were discounted at 3.5%. Probabilistic sensi-
tivity analyses were conducted. RESULTS: Compared to Pac-1w,
docetaxel yields higher mean health beneﬁts (2.01 vs. 1.73 life
years (LYs) and 1.18 vs. 1.03 quality-adjusted life-years (QALYs))
and costs less than the generic paclitaxel (13,518 vs. 15,008)
therefore permits the NHS to save 5400/LY and 9800/QALY.
Against Nab-paclitaxel, docetaxel produced higher LYs (2.01 vs.
1.62) and QALYs (1.18 vs. 0.96) but at a slightly higher cost
(13,518 vs. 11,640). Docetaxel had an incremental cost-
effectiveness ratio of4900/LYGand8600/QALYagainstNab-
paclitaxel. Given the indirect nature of this analysis, ICERs rely on
many assumptions and are sensitive to hazard ratios and to the
price of treatments. Conﬁdence intervals around the ICERs are
consequently high. CONCLUSION: Based on current evidence
docetaxel is cost-saving compared to generic pac-1w, which is
used but not approved in the UK, and cost effective compared to
Abraxane. Data from ongoing head-to-head clinical studies will
be necessary to reduce the wide conﬁdence intervals.
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OBJECTIVES: To evaluate the cost effectiveness of maintenance
rituximab therapy in the treatment of relapsed/refractory follicu-
lar NHL compared to observation alone. METHODS: A health
state transition model with 3 health states (progression-free,
progressive disease and death) was created utilising the Kaplan
Meier progression-free and overall survival data from the
EORTC20981 registration trial for the ﬁrst 24 months of the
model. A Weibull parametric function was then used to extrapo-
late survival for the remaining lifetime time-horizon of the
model, selection of the parametric function was based on good-
ness of ﬁt, relative to alternative parametric functions. The
assumed treatment effect of rituximab was limited to 5 years in
the model thereafter rituximab patients subsequently had a
monthly risk of death and disease progression equivalent to the
observation group. Patient characteristics were assumed equiva-
lent to the EORTC20981 study. QALYs were derived using
utility scores from a UK survey of over 200 follicular lymphoma
patients using the EQ-5D instrument, valued from the societal
perspective. Post protocol treatments were included, estimated
directly from the EORTC20981 study, routine patient monitor-
ing, drug administration and adverse event costs were also
included. RESULTS: Rituximab maintenance was associated
with an additional 0.89 QALYs compared to the observation arm
and total costs were 6886 higher in the maintenance arm. The
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